ORX (ORX) News
Follow ORX (ORX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Orexo Reports Sharply Lower Q3 Revenue and Wider Net Loss
EQUITY | Oct 22, 2026, 05:24 AM UTC
M
Orexo Reports Q3 2026 Results, DOJ Settlement in Principle and FDA Updates
Orexo said it filed its Q3 2026 interim report, reached a settlement in principle with the DOJ, submitted Izipry to the FDA, and received FDA acceptance of an IND for OX640. BARDA increased funding for OX390 by $2.99 mil
EQUITY | Oct 22, 2026, 05:00 AM UTC
M
Orexo Plans SEK 250M Rights Issue With 70% Backstop
Orexo AB (publ) plans a rights issue of approximately SEK 250M, pending EGM approval. About 70% of the issue is covered by subscriptions and underwriting. The company had SEK 118.7M in cash and equivalents as of August 3
EQUITY | Oct 06, 2026, 06:01 AM UTC
L
Orexo Resubmits NDA For Izipry To FDA
Orexo AB OMXSTO:ORX
REGULATION | Sep 29, 2026, 01:46 PM UTC
L
Orexo AB (publ.) (ORX) Resubmits IZIPRY NDA to FDA
Orexo resubmitted its NDA for IZIPRY (naloxone nasal powder) to the FDA on Sep 29, 2026, addressing a 2024 CRL. FDA acceptance and a review timeline are expected in the coming weeks.Material DetailsContext by AI AnalystT
REGULATION | Sep 29, 2026, 01:45 PM UTC
L
Orexo Announces FDA Acceptance Of Investigational New Drug Application
Orexo AB OMXSTO:ORX
REGULATION | Sep 14, 2026, 06:03 AM UTC
L
Orexo Announces FDA Acceptance of Investigational New Drug (IND) Application for OX640 for the Treatment of Anaphylaxis
Uppsala, Sweden — September 14th 2026 — Orexo AB (publ.) (STO:ORX) (OTCQX:ORXOY) today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OX640, a n
REGULATION | Sep 14, 2026, 06:01 AM UTC
L
Orexo US gets contract modification from BARDA
EQUITY | Sep 10, 2026, 06:05 AM UTC
L
BARDA modifies Orexo US contract, extending OX390 development to end-2027
Orexo AB said its US subsidiary Orexo US, Inc. received a contract modification from BARDA. The modification extends the initial development stage for the OX390 project to end of 2027.
EQUITY | Sep 10, 2026, 06:00 AM UTC
L
Orexo CFO Fredrik Järrsten resigns, to leave in December 2026
Orexo AB said Chief Financial Officer Fredrik Järrsten has resigned and will leave the company in December 2026.
EQUITY | Sep 01, 2026, 07:00 PM UTC
L
Orexo non-binding agreement in principle to settle US DOJ probe
Orexo (ORX) has reached a non-binding agreement in principle to settle an investigation by the US Department of Justice.
EQUITY | Aug 31, 2026, 06:00 AM UTC